NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the agreement, NAMSA will take ownership of WuXi’s facilities in Minnesota and Georgia.

Fan Weiqu, 62, killed 35 in a car rampage in Zhuhai, while Xu Jiajin, 21, fatally stabbed eight at a vocational school in Wuxi. Both acts, rooted in personal grievances, highlight a rise in “revenge ...

BEIJING (AP) -- China has executed two men who committed deadly attacks that killed dozens in November and raised concerns about a surge in what are called "revenge on society crimes," state media ...

Also in November, 21-year-old Xu Jiajin killed eight people and injured 17 others in a stabbing attack at his vocational school in the eastern city of Wuxi. Police said Wu had failed his ...

Xu Jiajin, who killed eight and injured 17 on a campus in Wuxi, Jiangsu province, in November, was executed on Monday after China's top court had approved his death sentence. The execution was ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

1 Day 603259 -0.99% DJIA 0.79% S&P 500 0.91% Health Care/Life Sciences 66.70% ...

Plus, news about Neur­i­zon: WuXi AppTec di­vests again: The com­pa­ny is sell­ing its US med­ical de­vice test­ing op­er­a­tions, in­clud­ing fa­cil­i­ties in Min­neso­ta and ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Senaparib is a PARP 1/2 inhibitor used to treat ovarian cancer. Credit: Jo Panuwat D/Shutterstock. IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing ...